share_log

三葉草生物-B：截至2024年2月29日止月份股份發行人的證券變動月報表

CLOVER BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month ended February 29, 2024

香港交易所 ·  Mar 4 02:12
Summary by Moomoo AI
三葉草生物製藥有限公司（「三葉草生物-B」）於2024年3月4日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年2月29日的公司股本變動情況。報告顯示，公司的法定/註冊股本及已發行股份在報告期內均無變動，維持在2,000,000,000股，每股面值0.0001美元，總額200,000美元。此外，公司的股份期權計劃包括首次公開發售前後的購股權計劃，其中首次公開發售前購股權計劃於2021年4月15日獲股東大會通過，首次公開發售後購股權計劃則於2021年9月26日獲通過。報告期內，兩項計劃均無股份期權行使或失效，結存股份期權數目分別為2,076,817股及37,346,265股。公司確認所有證券發行均已獲董事會授權，並符合香港聯合交易所有限公司證券上市規則的要求。
三葉草生物製藥有限公司（「三葉草生物-B」）於2024年3月4日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年2月29日的公司股本變動情況。報告顯示，公司的法定/註冊股本及已發行股份在報告期內均無變動，維持在2,000,000,000股，每股面值0.0001美元，總額200,000美元。此外，公司的股份期權計劃包括首次公開發售前後的購股權計劃，其中首次公開發售前購股權計劃於2021年4月15日獲股東大會通過，首次公開發售後購股權計劃則於2021年9月26日獲通過。報告期內，兩項計劃均無股份期權行使或失效，結存股份期權數目分別為2,076,817股及37,346,265股。公司確認所有證券發行均已獲董事會授權，並符合香港聯合交易所有限公司證券上市規則的要求。
Clover Biopharmaceuticals Limited (“Clover Bio-B”) filed with Hong Kong Trading and Clearing Limited on 4 March 2024 an updated Monthly Statement of Changes in Securities Reporting on the Company's share capital as of 29 February 2024. THE REPORT SHOWS THAT THE COMPANY'S STATUTORY/REGISTERED SHARE CAPITAL AND ISSUED SHARES REMAINED UNCHANGED DURING THE REPORTING PERIOD AT 2,000,000,000 SHARES WITH A FACE VALUE OF $0.0001 PER SHARE FOR A TOTAL AMOUNT OF $200,000. In addition, the Company's share option plan includes a pre-IPO and post-IPO share option plan, in which the Initial Public Offering pre-IPO share option plan was approved by the General Meeting on April 15, 2021, and the Initial Public Possession Option Plan was approved on September 26, 2021. During the reporting period, both plans did not exercise or expire with 2,076,817 shares and 37,346,265 shares outstanding. The Company confirms that all securities issuance has been authorised by the Board of Directors and complies with the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Clover Biopharmaceuticals Limited (“Clover Bio-B”) filed with Hong Kong Trading and Clearing Limited on 4 March 2024 an updated Monthly Statement of Changes in Securities Reporting on the Company's share capital as of 29 February 2024. THE REPORT SHOWS THAT THE COMPANY'S STATUTORY/REGISTERED SHARE CAPITAL AND ISSUED SHARES REMAINED UNCHANGED DURING THE REPORTING PERIOD AT 2,000,000,000 SHARES WITH A FACE VALUE OF $0.0001 PER SHARE FOR A TOTAL AMOUNT OF $200,000. In addition, the Company's share option plan includes a pre-IPO and post-IPO share option plan, in which the Initial Public Offering pre-IPO share option plan was approved by the General Meeting on April 15, 2021, and the Initial Public Possession Option Plan was approved on September 26, 2021. During the reporting period, both plans did not exercise or expire with 2,076,817 shares and 37,346,265 shares outstanding. The Company confirms that all securities issuance has been authorised by the Board of Directors and complies with the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more